Evidence map›Paper›PMID 27744351›Full record

ArticleNucleic acids research2016

RNA Editing TUTase 1: structural foundation of substrate recognition, complex interactions and drug targeting.

Lional Rajappa-Titu, Takuma Suematsu, Paola Munoz-Tello, Marius Long, Özlem Demir, Kevin J Cheng, Jason R Stagno, Hartmut Luecke, Rommie E Amaro, Inna Aphasizheva and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Nucleic acid therapeutics: Past, present, and future.Molecular therapy. Nucleic acids · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Lional Rajappa-TituDepartment of Molecular Biology, University of Geneva, 1211 Geneva, Switzerland.
Takuma SuematsuDepartment of Molecular and Cell Biology, Boston University School of Dental Medicine, Boston, MA 02118, USA.
Paola Munoz-TelloDepartment of Molecular Biology, University of Geneva, 1211 Geneva, Switzerland.
Marius LongDepartment of Molecular Biology, University of Geneva, 1211 Geneva, Switzerland.
Özlem DemirDepartment of Chemistry & Biochemistry and the National Biomedical Computation Resource, University of California, San Diego, La Jolla, CA 92093, USA.
Kevin J ChengDepartment of Chemistry & Biochemistry and the National Biomedical Computation Resource, University of California, San Diego, La Jolla, CA 92093, USA.
Jason R StagnoDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA.
Hartmut LueckeDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA.
Rommie E AmaroDepartment of Chemistry & Biochemistry and the National Biomedical Computation Resource, University of California, San Diego, La Jolla, CA 92093, USA.
Inna AphasizhevaDepartment of Molecular and Cell Biology, Boston University School of Dental Medicine, Boston, MA 02118, USA.
Ruslan AphasizhevDepartment of Molecular and Cell Biology, Boston University School of Dental Medicine, Boston, MA 02118, USA ruslana@bu.edu.
Stéphane ThoreDepartment of Molecular Biology, University of Geneva, 1211 Geneva, Switzerland stephane.thore@inserm.fr.
Boston University · USUniversity of California, San Diego · USUniversity of Geneva · CHUniversity of California, Irvine · USCentre National de la Recherche Scientifique · FR

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
National Biomedical Computation Resource - Competitive Revision SupplementP41GM103426 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AMARO, ROMMIE E · 2012 to 2019
$14.0M
Guide RNA Binding ComplexR01AI101057 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Ruslan Afasizhev · 2012 to 2026
$6.0M
Structures and Functions of RNA Editing TUTasesR01AI091914 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI AFASIZHEV, RUSLAN · 2011 to 2020
$4.4M
A Structural Systems Biology Approach to Drug DiscoveryDP2OD007237 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AMARO, ROMMIE E · 2010 to 2015
$2.9M
NCATS NIH HHS UL1 TR001414NIAID NIH HHS R01 AI091914NIAID NIH HHS R01 AI101057NIGMS NIH HHS P41 GM103426NIH HHS DP2 OD007237
6 · The paper itself

Abstract

Terminal uridyltransferases (TUTases) execute 3' RNA uridylation across protists, fungi, metazoan and plant species. Uridylation plays a particularly prominent role in RNA processing pathways of kinetoplastid protists typified by the causative agent of African sleeping sickness, Trypanosoma brucei In mitochondria of this pathogen, most mRNAs are internally modified by U-insertion/deletion editing while guide RNAs and rRNAs are U-tailed. The founding member of TUTase family, RNA editing TUTase 1 (RET1), functions as a subunit of the 3' processome in uridylation of gRNA precursors and mature guide RNAs. Along with KPAP1 poly(A) polymerase, RET1 also participates in mRNA translational activation. RET1 is divergent from human TUTases and is essential for parasite viability in the mammalian host and the insect vector. Given its robust in vitro activity, RET1 represents an attractive target for trypanocide development. Here, we report high-resolution crystal structures of the RET1 catalytic core alone and in complex with UTP analogs. These structures reveal a tight docking of the conserved nucleotidyl transferase bi-domain module with a RET1-specific C2H2 zinc finger and RNA recognition (RRM) domains. Furthermore, we define RET1 region required for incorporation into the 3' processome, determinants for RNA binding, subunit oligomerization and processive UTP incorporation, and predict druggable pockets.

Indexed as

Amino Acid SequenceCatalytic DomainCoatomer ProteinCrystallography, X-RayDrug DesignHydrogen BondingKineticsLeishmaniaMolecular Dynamics SimulationProtein BindingProtein Conformation, alpha-HelicalProtozoan ProteinsRNA EditingSubstrate SpecificityTrypanocidal AgentsCoatomer ProteinProtozoan ProteinsTrypanocidal Agents

Identifiers

PMID27744351
PMCPMC5159558
OpenAlexW2531471005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.